We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TSI

News List

Thrombolytic Science Granted a Second US Patent on Its Clot Dissolving Therapy, A Novel, Nature-inspired Treatment for Ischemic Strokes B3Cnewswire
January 06, 2022
Thrombolytic Science, LLC (TSI) has been granted a second patent by the USPTO. The patent was granted for a novel treatment applicable to ischemic stroke, one of the leading causes of morbidity and mortality.
TSI Reports Enrollment of First 10 Patients in its Phase 2 Ischemic Stroke Clinical Trial and Completion of its Phase 2 Study Protocol in Myocardial Infarction b3cnewswire
October 31, 2019
Thrombolytic Science, LLC (TSI) announced progress with 10 patients enrolled in its prospective, randomized, multicenter Phase 2 clinical trial, designed to confirm the safety and ...